Breaking News

BioMarin Acquires Repligen’s HDACi Portfolio

By Kristin Brooks | January 21, 2014

Includes potential treatment of Friedreich's Ataxia

BioMarin Pharmaceutical, Inc. has entered into an agreement to acquire Repligen's histone deacetylase inhibitor (HDACi) library and related intellectual property. The HDACi portfolio includes preclinical compounds with potential applications in Friedreich's ataxia and other neurological disorders. Repligen will receive an upfront payment of $2 million and potential future milestone and royalties for the development, regulatory approval and commercialization of compounds included in the agreement.
 
"This agreement represents a natural extension of BioMarin's business strategy of acquiring promising pre-clinical programs that we can successfully develop and commercialize for people with serious, unmet medical needs," said Jean-Jacques Bienaime, chief executive officer of BioMarin. "Fredreich's ataxia is a neurological disorder that affects tens of thousands of young people in the developed world and we look forward to the opportunity to move a compound into the clinic in this indication."

Related Contract Manufacturing:

blog comments powered by Disqus
  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • The Role of Alliances in Modern Drug Development

    The Role of Alliances in Modern Drug Development

    Dr. Claire Madden-Smith, Senior Vice President, Juniper Pharma Services||September 8, 2016
    Combining expertise to get drug candidates through development

  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent